

Serial No. 08/468,161
Case No. 19253IB
Page 3

On page 47, line 24, delete the phrase "Table 6 of".

On page 48, line 10, delete the phrase "Table 7 of".

In the Drawings

g. Note
Please delete the drawings for Figures 3a, 3b, 5, 6 and 7 and replace them with the new drawings of Figures 3a, 3b, 5, 6 and 7 submitted herewith.

REMARKS

Applicants respectfully thank Examiner Marshall for the telephonic interview with Applicants' Attorney Muthard regarding issues of formality that needed to be addressed with respect to the figures in the instant application. Applicants have amended the specification hereinabove and are submitting replacement pages of figures for Figures 3a, 3b, 5, 6 and 7. In light of these amendments and the amendments previously submitted by facsimile on November, 1997, Applicants contend that the application is now in condition for allowance.

Applicants have removed any reference to "Tables" from Figures 3a, 3b, 5, 6 and 7 and the Brief Description of the Figures section on pages 4 and 5. Applicants have also removed any reference to "Tables" in conjunction with Figures from the Examples.

Applicants have specifically designated the sequence listing number that corresponds to the individual amino acid sequences in Figure 2 in the Brief Description of Figure 2 found on page 4.

Applicants particularly note that the text at the top of the third column in Figure 7 as filed was missing the " μ " symbol in the designation of the EC₅₀ potencies. The potencies shown in that column are accurately in " μ M" and the activity represents. Applicants note that due to a typographical error the " μ " symbol was omitted from the figure. Applicants, in amending Figure 7 to remove the "Table 7" text, have also corrected the missing " μ " symbol.

C.


Serial No. 08/468,161
Case No. 19253IB
Page 4

Applicants contend that a person of ordinary skill in the art would readily appreciate that the activity of the conjugates described in Figure 7 against cells that secrete free PSA (LNCaP cells) should be in a range of 1-20 μM since the conjugates should have a cell killing activity against such cells that is comparable to the activity of doxorubicin against the same cells. Applicants note the discussion of activities of the conjugates in relation to the cytotoxic agent on page 15, lines 16-29, as filed. Applicants also note figure 4 as filed shows the concentration of the conjugates and doxorubicin that are tested as being in the μM or sub- μM range and not in the "M" (molar) range as Figure 7 in error showed. Applicants thus contend that the correction of the clearly unintentional typographical error does not add new matter and does not effect the condition of the application for allowance.

Applicants have also amended the Brief Description of Figures 4 and 7 to refer to the cytotoxicity activity values in the Figures as EC_{50} (effective concentrations), as shown in Figure 7 as filed. Applicants again contend that this was clearly an unintentional typographical error in the Brief Descriptions and therefore the correction does not add new matter.

Applicants respectfully contend that the Examiner's remaining rejections of the instant application have been addressed and obviated by the above amendments and remarks, and that Claims 13-19 as filed and amended and new Claim 21 are allowable and an early Notice of Allowance is earnestly solicited.

Respectfully submitted,

By: 

David A. Muthard
Reg. No. 35,297
Attorney for Applicant(s)

MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3903

Date: November 19, 1997